Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Thailand Approves New Therapeutic Medicine for Gout and Hyperuricemia
Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Brand Name : Urece
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 08, 2024
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Phase I
Sponsor : Fortress Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Brand Name : Urece
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2023
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase I
Sponsor : Fortress Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Approved
Sponsor : Urica Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Urece (dotinurad) is a potential best-in-class urate transporter inhibitor that is currently in Phase 1 clinical trial and being developed for the treatment of gout. It can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabso...
Brand Name : Urece
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Approved
Sponsor : Urica Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Approved
Sponsor : Fuji Yakuhin
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.
Brand Name : Urece
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2022
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Approved
Sponsor : Fuji Yakuhin
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dotinurad
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Fortress Biotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor that was approved for the treatment of gout and hyperuricemia in Japan in 2020.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 10, 2021
Lead Product(s) : Dotinurad
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Fortress Biotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eisai and FUJI YAKUHIN Conclude License Agreement
Details : Under this agreement, Eisai will proceed with the development of dotinurad in China.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 25, 2020
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?